We propose to investigate the biology of steroid-receptor-negative breast cancer, using three approaches: (1) We will fuse steroid-receptor-negative and -positive breast cancer cells to see if steroid-receptor-negativity, and its associated phenotype are suppressible (i.e., recessive genotypic characteristics); (2) We will fuse steroid-receptor-negative nuclei (karyoplasts) with steroid-receptor-positive cytoplasm (cytoplasts) to see if the steroid-receptor-negative nuclei can respond to a 17-B-estradiol in the presence of cytosolic steroid receptor; (3) We will use a monoclonal antibody directed against a steroid-receptor-positive human breast cancer cell line to probe the dynamic relationships of steroid-receptor-negative and -positive breast cancer in vitro and in vivo. Completion of these research projects should significantly increase our knowledge of the biology of steroid-receptor-negative breast cancer, a previously little-investigated problem in experimental oncology.
| Sledge Jr, G W; Loehrer Sr, P J; Roth, B J et al. (1988) Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 6:1811-4 |
| Broxmeyer, H E; Bicknell, D C; Gillis, S et al. (1986) Lactoferrin: affinity purification from human milk and polymorphonuclear neutrophils using monoclonal antibody (II 2C) to human lactoferrin, development of an immunoradiometric assay using II 2C, and myelopoietic regulation and receptor-binding characteri Blood Cells 11:429-46 |
| Sledge Jr, G W; Bicknell, D C; Harris, E L et al. (1986) Monoclonal antibody (II2C) to human lactoferrin inactivates the myelopoietic suppressive effect of human lactoferrin in vitro. Exp Hematol 14:333-7 |
